Compounds > glucagon
Page last updated: 2024-09-04

glucagon and uracil

glucagon has been researched along with uracil in 5 studies

Compound Research Comparison

Studies
(glucagon)		Trials
(glucagon)		Recent Studies (post-2010)
(glucagon)		Studies
(uracil)		Trials
(uracil)		Recent Studies (post-2010) (uracil)
26,0391,4983,05411,3007152,532

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carman Garcia, M; Nieto, A; R-Candela, JL1
Billington, CJ; Briggs, JE; Filice, GA; Norris, SA; Reding, MT; Sorensen, SW1
Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K2
Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H1

Other Studies

5 other study(ies) available for glucagon and uracil

ArticleYear
Effect of glucagon on spheroplasts of Escherichia coli.
    The Biochemical journal, 1971, Volume: 122, Issue:1

    Topics: Bacterial Proteins; Escherichia coli; Galactosidases; Glucagon; Leucine; Protoplasts; Uracil; Uridine

1971
Toxoplasma gondii: metabolism of intracellular tachyzoites is affected by host cell ATP production.
    Experimental parasitology, 1997, Volume: 85, Issue:1

    Topics: Adenosine Triphosphate; Adipocytes; Adipose Tissue, Brown; Animals; Body Temperature Regulation; CHO Cells; Cricetinae; Glucagon; Male; Mice; Mitochondria; Norepinephrine; Rats; Rats, Sprague-Dawley; Toxoplasma; Uracil

1997
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    European journal of pharmacology, 2008, Jul-07, Volume: 588, Issue:2-3

    Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glucagon; Glucagon-Like Peptide 1; Insulin; Male; Mice; Mice, Obese; Piperidines; Triglycerides; Uracil

2008
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    British journal of pharmacology, 2009, Volume: 157, Issue:3

    Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Degranulation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Eating; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Mice; Pioglitazone; Piperidines; Thiazolidinediones; Uracil

2009
Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
    Medical science monitor : international medical journal of experimental and clinical research, 2014, Apr-10, Volume: 20

    Topics: Aged; Asian People; Body Mass Index; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Japan; Kidney Function Tests; Male; Piperidines; Regression Analysis; Renal Insufficiency, Chronic; Steroids; Uracil; Vital Signs

2014